Multiple Sclerosis Clinical Trials in Illinois

31 recruiting studies across 1 city

Browse by City

All Trials in Illinois

Phase

Trial	Phase	Sponsor	Dist.
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS	N/A	Shirley Ryan AbilityLab	2 mi
Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain	N/A	Shirley Ryan AbilityLab	2 mi
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)	Phase 3	Amgen	2 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	Phase 3	Novartis Pharmaceuticals	2 mi
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)	N/A	Rush University Medical Center	2 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	2 mi
Nomad P-KAFO Study	N/A	Shirley Ryan AbilityLab	2 mi
Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.	N/A	University of Illinois at Chicago	2 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	2 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	2 mi
Functional Balance Intervention in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device	N/A	University of Illinois at Chicago	2 mi
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis	—	Shirley Ryan AbilityLab	2 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	2 mi
Home Based Functional Balance Intervention for Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	2 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis	Phase 3	Bristol-Myers Squibb	2 mi
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists	—	Northwestern University	2 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	2 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	2 mi
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Phase 4	National Institute of Allergy and Infectious Diseases (NIAID)	2 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	2 mi
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis	Phase 4	Northwestern University	2 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	2 mi
Intermittent Hypoxia in Persons With Multiple Sclerosis	N/A	Shirley Ryan AbilityLab	2 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	2 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	12 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease	—	TScan Therapeutics, Inc.	12 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis	Phase 3	Sanofi	20 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.